Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Ann Oncol
.
2019 Jun 1;30(6):1018.
doi: 10.1093/annonc/mdy530.
Authors
W Shi
,
T Jiang
,
P Nuciforo
,
C Hatzis
,
E Holmes
,
N Harbeck
,
C Sotiriou
,
L Peña
,
S Loi
,
D D Rosa
,
S Chia
,
A Wardley
,
T Ueno
,
J Rossari
,
H Eidtmann
,
A Armour
,
M Piccart-Gebhart
,
D L Rimm
,
J Baselga
,
L Pusztai
PMID:
30624555
PMCID:
PMC6594454
DOI:
10.1093/annonc/mdy530
No abstract available
Publication types
Published Erratum